Surmodics Inc (SRDX) 23.38 $SRDX Myriad Genetics Buys

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 2:18 PM

Surmodics Inc (SRDX) 23.38 $SRDX

Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), MYGN: 30.12 (-0.64), BAX: 44.11 (-1.85)

SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 23.38 (-0.68)

GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), GNC: 24.81 (-0.91)

Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), TMO: 146.34 (-5.80), BAX: 44.11 (-1.85), FEIC: 105.84 (-0.16)

IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), IDXX: 88.59 (-3.08)

Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), CPHD: 29.20 (-1.76)

Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), QGEN: 21.11 (-1.28)

ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), RMD: 60.69 (-3.39)

ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), RMD: 60.69 (-3.39)

Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), EW: 96.40 (-2.68)

Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 23.38 (-0.68), IRMD: 20.56 (-0.92), MASI: 50.98 (-1.40), BAX: 44.11 (-1.85)

Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 23.38 (-0.68), MASI: 50.98 (-1.40), BAX: 44.11 (-1.85), EW: 96.40 (-2.68)

Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 23.38 (-0.68), MASI: 50.98 (-1.40), EW: 96.40 (-2.68), QSII: 11.84 (-0.24)

Boston Scientific's Full-Body MRI SCS System Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:20AM CDT
Boston Scientific's (BSX) Precision Montage MRI SCS allows patients to undergo a full-body 1.5 Tesla MRI scan while also delivering multiple waveforms.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), LMAT: 14.44 (-0.38)

Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 23.38 (-0.68), IRMD: 20.56 (-0.92), MASI: 50.98 (-1.40), EW: 96.40 (-2.68)

STERIS (STE) Misses on Q4 Earnings, Higher Tax a Concern
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:32AM CDT
STERIS (STE) ended fiscal 2016 on a disappointing note, with its fourth-quarter results missing the Zacks Consensus Estimate on both the fronts
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), STE: 65.35 (-4.04), BAX: 44.11 (-1.85)

Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 23.38 (-0.68), MASI: 50.98 (-1.40), PETS: 18.48 (-0.02), EW: 96.40 (-2.68)

Bristol-Myers' Opdivo Wins FDA Nod for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:26AM CDT
Bristol-Myers' (BMY) Opdivo was approved for the treatment of patients with classical Hodgkin lymphoma (cHL).
SRDX: 23.38 (-0.68), ANIP: 54.52 (-1.75), RTRX: 17.88 (-0.61), BMY: 71.20 (-1.44)

Edwards Lifesciences Presents Positive Data on Sapien3
Zacks Equity Research - Zacks Investment Research - Wed May 18, 7:20AM CDT
Results from this study demonstrated a survival rate of 98.1% at the end of 30 days, for patients implanted with a Sapien 3 valve from Edwards Lifesciences (EW).
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), BAX: 44.11 (-1.85), EW: 96.40 (-2.68)

Myriad Genetics Brings myVectra Web Portal for RA Patients
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:04AM CDT
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.
BSX: 22.59 (-0.38), SRDX: 23.38 (-0.68), MYGN: 30.12 (-0.64), BAX: 44.11 (-1.85)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Newfold Digital Revamps Leadership for Growth Surge

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Ajman Tourism Department Hits Internal Audit Milestone

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...